Vitamin D3 and K2: Why the VITAL Trial's Nuanced Results Are Being Misread, Why Standard Lab Reference Ranges Set the Bar Too Low, and Why You Can't Optimize Vitamin D Without Also Addressing Magnesium and K2
Updated: June 2026vitamin D supplement · vitamin D3 supplement · vitamin D benefits · vitamin D deficiency · vitamin D deficiency symptoms · how much vitamin D per day · vitamin D3 dose · vitamin D 2000 IU · vitamin D 5000 IU · vitamin D 10000 IU · optimal vitamin D level · vitamin D blood test · 25-OH-D test · 25 hydroxyvitamin D · vitamin D normal range · vitamin D optimal range · vitamin D 40 ng/mL · vitamin D 60 ng/mL · VITAL trial vitamin D · VITAL trial results · Manson 2019 vitamin D · vitamin D cancer · vitamin D cancer mortality · vitamin D cancer prevention · vitamin D cardiovascular · vitamin D heart disease · vitamin D immune system · vitamin D autoimmune · vitamin D receptor VDR · VDR polymorphism · vitamin D receptor tissues · 1,25 dihydroxyvitamin D · calcitriol · calcidiol · vitamin D activation · vitamin D kidney · vitamin D liver · vitamin D sun · sun exposure vitamin D · how much sun for vitamin D · vitamin D synthesis skin · UVB vitamin D · latitude vitamin D · winter vitamin D · vitamin D and magnesium · magnesium vitamin D conversion · vitamin D without magnesium · vitamin D3 vs D2 · ergocalciferol vs cholecalciferol · vitamin D2 absorption · D3 better than D2 · vitamin K2 · vitamin K2 MK-7 · vitamin K2 MK-4 · MK-7 vs MK-4 · menaquinone-7 · menaquinone-4 · vitamin K2 bone · vitamin K2 cardiovascular · K2 calcification · K2 arterial calcification · vitamin K2 osteocalcin · matrix GLA protein K2 · K2 and D3 together · vitamin D K2 combination · K2 D3 stack · why take K2 with D3 · vitamin D calcium · vitamin D hypercalcemia · vitamin D toxicity · vitamin D upper limit · vitamin D cofactors · vitamin D with fat · vitamin D fat soluble · vitamin D morning or night · vitamin D timing · vitamin D with food
Vitamin D is unusual among vitamins because it functions as a hormone. Unlike most vitamins that act as enzyme cofactors in specific metabolic pathways, vitamin D (specifically its active form, 1,25-dihydroxyvitamin D / calcitriol) binds to the vitamin D receptor (VDR) — a nuclear receptor expressed in at least 37 different tissue types including bone, kidney, small intestine, brain, immune cells, pancreatic beta cells, vascular endothelium, and skeletal muscle. When calcitriol binds VDR, the complex translocates to the nucleus and regulates the transcription of hundreds of genes. Vitamin D deficiency therefore has multi-system consequences that extend far beyond bone health — the condition most people associate it with.
The VITAL trial (Vitamin D and Omega-3 Trial, Manson et al. 2019 NEJM) is the largest and most rigorous RCT of vitamin D supplementation ever conducted: N=25,871 adults followed for 5.3 years with 2,000 IU vitamin D3 per day versus placebo. Its results have been widely mischaracterized. The headline — "no significant reduction in primary cardiovascular events or cancer incidence" — was taken by many to mean "vitamin D supplements don't work." But VITAL showed substantial reductions in cancer mortality (−25%), metastatic cancer (−28%), and significant benefits in people with normal BMI and lower baseline D levels. The story is more nuanced than the headlines captured.
−25%
cancer mortality in VITAL (the signal everyone missed) — VITAL trial (Manson 2019 NEJM, N=25,871, 2000 IU/day D3 vs placebo, 5.3 years): primary endpoints (cancer incidence and major cardiovascular events): no significant reduction — this was the headline; secondary and exploratory analyses: cancer mortality: −25% reduction (HR 0.75, 95% CI 0.59–0.96, p=0.02) — statistically significant; metastatic or fatal cancer: −28% reduction (HR 0.72, p=0.02); among people with BMI <25 (healthy weight): cancer incidence −24% reduction (HR 0.76, p=0.04); among participants with lower baseline 25-OH-D: larger benefit in multiple outcomes; the reason primary cancer incidence was not reduced: supplementation in an already D-sufficient population for only 5.3 years likely does not prevent tumor initiation, but it appears to reduce cancer progression and metastasis — which is when it matters most; VITAL-B sub-analysis: reduction in autoimmune disease (−22% in years 3–5) with vitamin D3 + omega-3; subsequent VITAL publications (2022–2025): reductions in falls, fractures in osteoporotic individuals, and T2D incidence in prediabetes added to the benefit picture; the blanket dismissal of vitamin D supplementation based on VITAL's primary endpoint was scientifically illiterate
37 tissues
VDR expression — the breadth of vitamin D receptor distribution in the body explains why vitamin D deficiency causes symptoms across so many organ systems; key VDR-expressing tissues and their D-dependent functions: bone (osteoblast differentiation, calcium absorption); kidney (calcium and phosphate regulation); small intestine (calcium absorption — D3 increases calcium absorption from ~10–15% to 30–40%); immune cells (T-cell and macrophage modulation; D3 promotes regulatory T-cells, suppresses Th17 pro-inflammatory cells); pancreatic beta cells (insulin secretion; VDR knockout animals develop impaired glucose tolerance); skeletal muscle (muscle protein synthesis and fiber type; VDR knockout produces myopathy); brain (hippocampal neurogenesis, neurotrophin expression); vascular endothelium (eNOS activation, blood pressure modulation); thyroid (thyroid hormone receptor cross-talk); the clinical consequence: true vitamin D deficiency (<20 ng/mL) produces effects ranging from osteomalacia (bone softening) and proximal muscle weakness to impaired immune defense, increased autoimmune risk, impaired glucose metabolism, and elevated blood pressure; insufficiency (20–30 ng/mL) produces subtler but real impairments across these same systems; this breadth is why vitamin D is one of the most impactful single interventions in populations with deficiency
Mg-dep.
the magnesium connection — the conversion of vitamin D to its active form involves two successive hydroxylation steps: step 1: 25-hydroxylation in the liver (cholecalciferol → 25-hydroxyvitamin D / calcidiol); step 2: 1α-hydroxylation in the kidney (calcidiol → 1,25-dihydroxyvitamin D / calcitriol); both hydroxylase enzymes are cytochrome P450 enzymes (CYP27B1, CYP2R1) that require magnesium as a cofactor; in magnesium deficiency: these hydroxylase enzymes function at reduced efficiency; patients may have "normal" 25-OH-D levels on testing but impaired conversion to active calcitriol; clinical pattern: patient takes large doses of vitamin D, serum 25-OH-D rises normally, but they continue to have symptoms consistent with vitamin D deficiency; clinical correction: ensuring magnesium adequacy (RBC Mg test preferred over serum) before or alongside vitamin D optimization often dramatically improves outcome; the reverse also applies: vitamin D supplementation increases the demand for magnesium (D3 upregulates enzymes that consume magnesium); supplementing high-dose D3 without magnesium can precipitate hypomagnesemia symptoms; practical corollary: vitamin D3 and magnesium glycinate are best supplemented together
K2 MK-7
why K2 belongs in every D3 protocol — vitamin D3 significantly increases intestinal calcium absorption; without adequate vitamin K2, this calcium may not be directed appropriately to bone and teeth — it can deposit in soft tissues and arteries instead; vitamin K2 activates two critical calcium-directing proteins: (1) osteocalcin (in bone): K2-dependent carboxylation of osteocalcin is required for calcium binding in bone matrix; undercarboxylated osteocalcin = poor calcium incorporation into bone; (2) matrix GLA protein (MGP, in vascular smooth muscle): K2-dependent MGP is the most potent known inhibitor of vascular calcification; K2 deficiency → underactivated MGP → calcium deposits in arterial walls → arterial stiffness → cardiovascular disease; EPIC-Heidelberg study (Geleijnse 2004, Journal of Nutrition, N=4,807): highest K2 intake associated with −57% coronary heart disease mortality vs lowest quintile; K2 is NOT the same as K1 (phylloquinone from leafy greens); K1 is primarily used for clotting factor activation; K2 (menaquinone) is the form that activates osteocalcin and MGP; K2 forms: MK-7 (menaquinone-7): derived from natto fermentation; half-life 72 hours → once-daily dosing effective; best studied for osteocalcin activation; MK-4 (menaquinone-4): synthetic form; half-life ~4 hours → multiple daily doses needed; dose: MK-7 90–200mcg/day; MK-4 1.5–15mg/day (higher dose required due to pharmacokinetics)
Ready to build the full protocol?
The Longevity Stack ranks 20+ compounds by evidence tier — the full biomarker panel, VO2 max protocol, sleep science, hormone chapter, and three budget-level stacks, built from the same research on this page.
Get the Longevity Stack → $19
Vitamin D Status Reference Guide
| 25-OH-D Level | Standard Lab Classification | Functional Medicine View | Implications |
|---|
| <20 ng/mL (<50 nmol/L) | Deficient | Severe deficiency | High fracture risk; impaired immune function; muscle weakness; elevated PTH driving bone resorption; requires prompt correction |
| 20–29 ng/mL | Insufficient (some labs say sufficient) | Insufficient | Meets minimum for bone health by some standards; sub-optimal for immune, cardiovascular, cancer-preventive, and neurological functions |
| 30–39 ng/mL | Sufficient | Low-normal | Standard lab "normal" floor; below optimal for extra-skeletal functions; many large epidemiological studies show continued dose-response benefit above this level |
| 40–60 ng/mL | Sufficient | Optimal target range | Range associated with lowest all-cause mortality in most large observational studies (Garland et al., GrassrootsHealth data); optimal VDR gene expression across extra-skeletal tissues |
| 60–80 ng/mL | Sufficient | Upper optimal (some protocols) | Some researchers target this range; limited evidence of additional benefit above 60 ng/mL; still considered safe in most adults |
| >100 ng/mL | Potentially toxic | Toxic range — requires medical supervision | Hypercalcemia risk; kidney stone risk; soft tissue calcification; associated with doses typically >10,000 IU/day without K2 in susceptible individuals |
D3 + K2 + Magnesium Optimization Protocol
Test first: serum 25-OH-D before supplementing; also test RBC magnesium; testing cost is low and identifies whether you're in deficiency vs insufficiency range (dose differs substantially); most physicians will order 25-OH-D with a routine blood panel; home testing available (GrassrootsHealth D*action test: finger-prick mail-in).
Dosing by baseline 25-OH-D: <20 ng/mL: 5,000–10,000 IU D3/day for 8–12 weeks, then retest; 20–30 ng/mL: 3,000–5,000 IU/day; 30–40 ng/mL: 2,000 IU/day (VITAL dose) to maintain or modestly increase; already 40+ ng/mL: 1,000–2,000 IU/day for maintenance; note: individual response to vitamin D varies 2–5 fold based on VDR polymorphisms, body fat (D3 is fat-soluble and sequesters in adipose tissue — higher BMI = more D3 needed for equivalent serum level), baseline gut absorption, and magnesium status.
K2 MK-7: 100–200mcg/day with the largest meal (fat enhances absorption); MK-7 has the best pharmacokinetic profile for once-daily supplementation; fermented foods with K2: natto (highest K2 food source at ~1,000mcg/100g — mostly MK-7); some aged cheeses (Gouda, Brie contain MK-4 and MK-9); these dietary sources can meaningfully contribute to K2 intake.
Magnesium co-supplementation: magnesium glycinate 200–400mg elemental magnesium/day (see full magnesium guide); particularly important if supplementing >2,000 IU D3/day; retest 25-OH-D at 3 months; target 40–60 ng/mL; adjust dose accordingly and retest annually thereafter.
Sun exposure protocol (ideally, before supplementation): UVB radiation (290–315nm) converts 7-dehydrocholesterol in skin to previtamin D3; effective sun exposure requires: skin exposure (arms, legs, torso — not just face/hands); time around solar noon (UVB angle); minimal sunscreen (SPF 30+ blocks 97% of UVB); season/latitude dependent (above 37°N latitude, essentially no effective D3 synthesis in winter months); skin type dependent (darker skin requires longer exposure); typical guideline: 10–20 minutes of midday sun on significant skin surface (arms and legs) produces 1,000–5,000 IU D3 depending on skin tone and conditions; this is the most physiologically natural route to D3 sufficiency, with built-in toxicity protection (excess previtamin D3 is photodegraded by UVB itself).
D3 + K2 MK-7 →
Vitamin D Home Test →
Complete the foundational supplement stack
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.